![Silvia Noiman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Silvia Noiman
Directeur Général chez Imel Biotherapeutics, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Sumit Aggarwal | M | - | 3 ans | |
Martijn Kleijwegt | M | 69 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 5 ans |
Dori Pelled | M | - |
Imel Biotherapeutics, Inc.
![]() Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | 5 ans |
Daniel Geffken | M | 67 | 4 ans | |
Alan Walts | M | 64 | 3 ans | |
Luc Dochez | M | 49 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 5 ans |
Anders Hinsby | M | 51 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 4 ans |
Josh Mandel-Brehm | M | 41 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 5 ans |
Amy Schulman | F | 63 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 4 ans |
Klaus Breiner | M | - |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | - |
Rémi Droller | M | 48 |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | - |
Felice Verduyn-van Weegen | F | - |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 5 ans |
Micah Mackison | M | - |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 2 ans |
Anne Bechet | F | - |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | 5 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Gregory C. Williams | M | 65 | 3 ans | |
Stephen MacDonald | M | 53 | 2 ans | |
Neil Belloff | M | 64 | 3 ans | |
Tomer Kariv | M | 62 | 6 ans | |
Ran Nussbaum | M | 51 |
cCAM Biotherapeutics Ltd.
![]() cCAM Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel. | 9 ans |
Raj Bhikhu Parekh | M | 63 | 1 ans | |
Gary D Rakers | M | - | 1 ans | |
Matt Goddeeris | M | - | - | |
Zafrira Avnur | M | 73 | 5 ans | |
Brett Hagen | M | 51 | - | |
Gal Markel | M | - |
cCAM Biotherapeutics Ltd.
![]() cCAM Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel. | 5 ans |
Gregory Weaver | M | 68 | 3 ans | |
Robert E. Ward | M | 66 | 3 ans | |
Gadi Veinrib | M | 45 | 5 ans | |
Jasbir Seehra | M | 68 | 4 ans | |
Vijay Modur | M | - | 2 ans | |
Tehila Ben-Moshe | M | - |
cCAM Biotherapeutics Ltd.
![]() cCAM Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel. | 6 ans |
Thomas P. Haverty | M | - | - | |
David P. Snow | M | 62 | 2 ans | |
Rose Villandry | F | - | 2 ans | |
Aya Jakobovits | M | 71 |
cCAM Biotherapeutics Ltd.
![]() cCAM Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel. | 2 ans |
Anja Harmeier | M | - |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | - |
Robert A. Heft | M | 69 | - | |
Pedro Huertas | M | 69 | 3 ans | |
Martie Griffin | F | - | - | |
Moshe Arkin | M | 69 |
cCAM Biotherapeutics Ltd.
![]() cCAM Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel. | 3 ans |
Anat Nursella | F | - |
cCAM Biotherapeutics Ltd.
![]() cCAM Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel. | 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 26 | 63,41% |
Pays-Bas | 11 | 26,83% |
Israël | 6 | 14,63% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Silvia Noiman
- Réseau Personnel